NCI Frederick Cancer Research and Development Center (NCI-FCRDC), P.O. Box B, Frederick, Maryland 21702-1201

A -- SUPERNATANTS FOR LYMPHOMA VACCINE SOL S00-60 DUE 122799 POC Heather Wells -- 301-846-1520 E-MAIL: Click here to contact the contract specialist via., hwells@mail.ncifcrf.gov. SAIC Frederick, as Operations and Technical Support contractor to the National Cancer Institute (NCI) for the Frederick Cancer Research and Development Center is seeking a subcontractor which, following protocols provided by the NCI, will generate supernatants containing patient specific immunoglobulins (PSI) for use in the production of experimental vaccines for B-cell lymphoma. These supernatants will come from hybridoma cell lines generated by the fusion of the patients tumor cells with a mouse-human heterohybridoma cell line. Supernatants from these fusion lines will contain the same PSI as the original tumor cells. The subcontractor will be required to: (1) expand the fusion cell lines (2) generate supernatants containing the PSI and (3) assay these supernatants for PSI, all under GLP or GMP as necessary. Supernatants will be generated in small, hollow-fiber bioreactors according to a protocol provided by the NCI, and should be shown by the subcontractor to be sterile, mycoplasma-free, and non-reactive in an in vitro adventitious-virus assay. It is anticipated that the subcontractor will produce 30-50 supernatants per year, with each supernatant containing a minimum of 100mg PSI. Interested subcontractors should immediately contact the POC listed herein. Posted 12/20/99 (W-SN410122). (0354)

Loren Data Corp. http://www.ld.com (SYN# 0009 19991222\A-0009.SOL)